A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia

@article{Chappell2009A1S,
  title={A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia},
  author={A. Chappell and G. Littlejohn and D. Kajdasz and M. Scheinberg and D. D'souza and H. Moldofsky},
  journal={The Clinical Journal of Pain},
  year={2009},
  volume={25},
  pages={365-375}
}
ObjectivesEvaluate the efficacy and safety of duloxetine at doses up to 120 mg once daily in patients with fibromyalgia. MethodsThis was a phase 3, 60-week study, which included an 8-week open-label period followed by a 52-week, randomized, double-blind period. Patients received duloxetine 30 mg daily for 1 week and duloxetine 60 mg daily for 7 weeks and were then randomized to receive either 60 or 120 mg daily (1:2 ratio). ResultsEnrolled patients (N=350, 95.7% female) exhibited moderate… Expand
66 Citations
An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia
  • 11
  • Highly Influenced
Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective
  • 24
Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
  • 8
Duloxetine: A Review of Its Safety and Efficacy in the Management of Fibromyalgia Syndrome
  • 4
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
  • 300
...
1
2
3
4
5
...